This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"


24th March 2020

QED is actively assessing the impact that COVID-19 may have on their work and want to assure patients and families that they are is committed to moving forward with the program to develop Infigratinib as an option for children with achondroplasia. But QED also must acknowledge that we are facing unforeseen challenges with this global pandemic.
COVID-19 may cause some delays in QED studies, and the company hopes will be temporary as physicians focus on fighting the virus and families stay away from hospitals for non-essential care. QED remains hopeful that the clinical trial for infigratinib in achondroplasia can start in the near future, with the exact timing dependent on how this dynamic situation evolves. QED commitment is to conduct the studies in children with achondroplasia at a safe and appropriate time. More information about the PROPEL 2 study here.


QED remains committed to the achondroplasia community and, first and foremost, to the safety of any child who participates in QED studies. The company will keep patient groups, patients, and families up to date as the situation evolves and will inform of key developments from QED.

QED invites you to read a message from Neil Kumar, the CEO of BridgeBio, the parent company of QED here. 

If you would like more information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

Please keep safe

To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.